Published in Proc Natl Acad Sci U S A on January 28, 2008
Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol (2011) 8.37
Preexistence and clonal selection of MET amplification in EGFR mutant NSCLC. Cancer Cell (2010) 7.78
Novel mutant-selective EGFR kinase inhibitors against EGFR T790M. Nature (2009) 7.05
Mechanisms of resistance to crizotinib in patients with ALK gene rearranged non-small cell lung cancer. Clin Cancer Res (2012) 6.23
Rational, biologically based treatment of EGFR-mutant non-small-cell lung cancer. Nat Rev Cancer (2010) 5.82
Activation of the AXL kinase causes resistance to EGFR-targeted therapy in lung cancer. Nat Genet (2012) 5.64
Optimization of dosing for EGFR-mutant non-small cell lung cancer with evolutionary cancer modeling. Sci Transl Med (2011) 4.91
AZD9291, an irreversible EGFR TKI, overcomes T790M-mediated resistance to EGFR inhibitors in lung cancer. Cancer Discov (2014) 4.55
Rebiopsy of lung cancer patients with acquired resistance to EGFR inhibitors and enhanced detection of the T790M mutation using a locked nucleic acid-based assay. Clin Cancer Res (2011) 4.16
MED12 controls the response to multiple cancer drugs through regulation of TGF-β receptor signaling. Cell (2012) 4.01
Activating and resistance mutations of EGFR in non-small-cell lung cancer: role in clinical response to EGFR tyrosine kinase inhibitors. Oncogene (2009) 3.86
Understanding resistance to EGFR inhibitors-impact on future treatment strategies. Nat Rev Clin Oncol (2010) 3.80
Acquired resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant lung cancer: distinct natural history of patients with tumors harboring the T790M mutation. Clin Cancer Res (2010) 3.68
Factors underlying sensitivity of cancers to small-molecule kinase inhibitors. Nat Rev Drug Discov (2009) 3.64
Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancers dependent on the epidermal growth factor receptor pathway. Clin Lung Cancer (2009) 3.37
Targeting the PI3K signaling pathway in cancer. Curr Opin Genet Dev (2009) 3.35
Liquid biopsy: monitoring cancer-genetics in the blood. Nat Rev Clin Oncol (2013) 3.34
The quest to overcome resistance to EGFR-targeted therapies in cancer. Nat Med (2013) 3.20
Activation of tyrosine kinases by mutation of the gatekeeper threonine. Nat Struct Mol Biol (2008) 3.18
Dual targeting of EGFR can overcome a major drug resistance mutation in mouse models of EGFR mutant lung cancer. J Clin Invest (2009) 3.14
Combinatorial drug therapy for cancer in the post-genomic era. Nat Biotechnol (2012) 3.10
Discovery of a mutant-selective covalent inhibitor of EGFR that overcomes T790M-mediated resistance in NSCLC. Cancer Discov (2013) 2.93
Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease. J Clin Oncol (2013) 2.90
KIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patients. Proc Natl Acad Sci U S A (2009) 2.84
New strategies in overcoming acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in lung cancer. Clin Cancer Res (2011) 2.74
Transformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of origin. Lancet Oncol (2015) 2.73
Genetic predictors of MEK dependence in non-small cell lung cancer. Cancer Res (2008) 2.71
Differential sensitivity of glioma- versus lung cancer-specific EGFR mutations to EGFR kinase inhibitors. Cancer Discov (2012) 2.61
Amplification of EGFR T790M causes resistance to an irreversible EGFR inhibitor. Oncogene (2010) 2.53
A genome-scale RNA interference screen implicates NF1 loss in resistance to RAF inhibition. Cancer Discov (2013) 2.49
Reactivation of ERK signaling causes resistance to EGFR kinase inhibitors. Cancer Discov (2012) 2.47
ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics. Cancer Cell (2014) 2.44
Acquired resistance to epidermal growth factor receptor kinase inhibitors associated with a novel T854A mutation in a patient with EGFR-mutant lung adenocarcinoma. Clin Cancer Res (2008) 2.34
Mechanistic insight into ALK receptor tyrosine kinase in human cancer biology. Nat Rev Cancer (2013) 2.17
PI3K-targeted therapy can be evaded by gene amplification along the MYC-eukaryotic translation initiation factor 4E (eIF4E) axis. Proc Natl Acad Sci U S A (2011) 2.14
Nitrile-containing pharmaceuticals: efficacious roles of the nitrile pharmacophore. J Med Chem (2010) 2.12
Unleashing the power of inhibitors of oncogenic kinases through BH3 mimetics. Nat Rev Cancer (2009) 2.02
Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib. Clin Cancer Res (2008) 2.00
Treating ALK-positive lung cancer--early successes and future challenges. Nat Rev Clin Oncol (2012) 1.97
Differential inhibitor sensitivity of anaplastic lymphoma kinase variants found in neuroblastoma. Sci Transl Med (2011) 1.96
Hsp90 inhibition suppresses mutant EGFR-T790M signaling and overcomes kinase inhibitor resistance. Cancer Res (2008) 1.95
Classic and contemporary approaches to modeling biochemical reactions. Genes Dev (2010) 1.90
Emerging paradigms in the development of resistance to tyrosine kinase inhibitors in lung cancer. J Clin Oncol (2013) 1.88
Dual inhibition of EGFR with afatinib and cetuximab in kinase inhibitor-resistant EGFR-mutant lung cancer with and without T790M mutations. Cancer Discov (2014) 1.88
Noncovalent wild-type-sparing inhibitors of EGFR T790M. Cancer Discov (2012) 1.86
c-MET as a potential therapeutic target and biomarker in cancer. Ther Adv Med Oncol (2011) 1.81
Convergence between Wnt-β-catenin and EGFR signaling in cancer. Mol Cancer (2010) 1.74
Phase I dose-escalation study of the pan-HER inhibitor, PF299804, in patients with advanced malignant solid tumors. Clin Cancer Res (2011) 1.66
Equally potent inhibition of c-Src and Abl by compounds that recognize inactive kinase conformations. Cancer Res (2009) 1.64
A comprehensive review of the preclinical efficacy profile of the ErbB family blocker afatinib in cancer. Naunyn Schmiedebergs Arch Pharmacol (2014) 1.63
Overcoming EGFR(T790M) and EGFR(C797S) resistance with mutant-selective allosteric inhibitors. Nature (2016) 1.62
Structural, biochemical, and clinical characterization of epidermal growth factor receptor (EGFR) exon 20 insertion mutations in lung cancer. Sci Transl Med (2013) 1.56
Rapid phospho-turnover by receptor tyrosine kinases impacts downstream signaling and drug binding. Mol Cell (2011) 1.55
EGFR-mutated lung cancer: a paradigm of molecular oncology. Oncotarget (2010) 1.53
A chemical biology strategy to analyze rheostat-like protein kinase-dependent regulation. Chem Biol (2013) 1.50
EGFR exon 19 insertions: a new family of sensitizing EGFR mutations in lung adenocarcinoma. Clin Cancer Res (2011) 1.50
A structure-guided approach to creating covalent FGFR inhibitors. Chem Biol (2010) 1.46
Therapeutic targeting of epidermal growth factor receptor in human cancer: successes and limitations. Chin J Cancer (2011) 1.45
Simultaneous visualization of the extracellular and cytoplasmic domains of the epidermal growth factor receptor. Nat Struct Mol Biol (2011) 1.45
The challenge of developing robust drugs to overcome resistance. Drug Discov Today (2011) 1.43
Known and putative mechanisms of resistance to EGFR targeted therapies in NSCLC patients with EGFR mutations-a review. Transl Lung Cancer Res (2015) 1.43
Mechanisms of resistance to EGFR TKIs and development of a new generation of drugs in non-small-cell lung cancer. J Biomed Biotechnol (2011) 1.42
Structural and mechanistic underpinnings of the differential drug sensitivity of EGFR mutations in non-small cell lung cancer. Biochim Biophys Acta (2009) 1.35
Redox regulation of epidermal growth factor receptor signaling through cysteine oxidation. Biochemistry (2012) 1.35
Differential sensitivity of ERBB2 kinase domain mutations towards lapatinib. PLoS One (2011) 1.35
Mechanisms of Resistance to Epidermal Growth Factor Receptor Inhibitors and Novel Therapeutic Strategies to Overcome Resistance in NSCLC Patients. Chemother Res Pract (2012) 1.34
Repurposing of bisphosphonates for the prevention and therapy of nonsmall cell lung and breast cancer. Proc Natl Acad Sci U S A (2014) 1.34
Molecular mechanisms of disease-causing missense mutations. J Mol Biol (2013) 1.31
Targeted therapy for non-small cell lung cancer: current standards and the promise of the future. Transl Lung Cancer Res (2015) 1.29
Mechanisms of drug resistance in kinases. Expert Opin Investig Drugs (2011) 1.29
EGFR Mutations and Resistance to Irreversible Pyrimidine-Based EGFR Inhibitors. Clin Cancer Res (2015) 1.28
Preclinical development of molecular-targeted agents for cancer. Nat Rev Clin Oncol (2010) 1.27
Combined EGFR/MET or EGFR/HSP90 inhibition is effective in the treatment of lung cancers codriven by mutant EGFR containing T790M and MET. Cancer Res (2012) 1.27
Reduced NF1 expression confers resistance to EGFR inhibition in lung cancer. Cancer Discov (2014) 1.27
Strategies for discovering and derisking covalent, irreversible enzyme inhibitors. Future Med Chem (2010) 1.27
Cancer driver mutations in protein kinase genes. Cancer Lett (2008) 1.24
Bisphosphonates inactivate human EGFRs to exert antitumor actions. Proc Natl Acad Sci U S A (2014) 1.24
Acquired resistance to drugs targeting receptor tyrosine kinases. Biochem Pharmacol (2011) 1.23
Mechanism for activation of mutated epidermal growth factor receptors in lung cancer. Proc Natl Acad Sci U S A (2013) 1.22
Effects of pharmacokinetic processes and varied dosing schedules on the dynamics of acquired resistance to erlotinib in EGFR-mutant lung cancer. J Thorac Oncol (2012) 1.22
Molecular pathways: resistance to kinase inhibitors and implications for therapeutic strategies. Clin Cancer Res (2014) 1.21
Mechanisms of resistance to EGFR tyrosine kinase inhibitors. Acta Pharm Sin B (2015) 1.20
Perspectives for the use of structural information and chemical genetics to develop inhibitors of Janus kinases. J Cell Mol Med (2010) 1.19
Membrane rafts and caveolae in cardiovascular signaling. Curr Opin Nephrol Hypertens (2009) 1.19
EGFR-mutant lung adenocarcinomas treated first-line with the novel EGFR inhibitor, XL647, can subsequently retain moderate sensitivity to erlotinib. J Thorac Oncol (2012) 1.18
Resistance to ROS1 inhibition mediated by EGFR pathway activation in non-small cell lung cancer. PLoS One (2013) 1.17
Targeted therapies for lung cancer: clinical experience and novel agents. Cancer J (2011) 1.17
Re-Treatment with EGFR-TKIs in NSCLC Patients Who Developed Acquired Resistance. J Pers Med (2014) 1.17
Structural and spectroscopic analysis of the kinase inhibitor bosutinib and an isomer of bosutinib binding to the Abl tyrosine kinase domain. PLoS One (2012) 1.17
Rational approaches to improving selectivity in drug design. J Med Chem (2012) 1.16
Epidermal growth factor receptor (EGFR) mutations in lung cancer: preclinical and clinical data. Braz J Med Biol Res (2014) 1.16
In vitro enzymatic characterization of near full length EGFR in activated and inhibited states. Biochemistry (2009) 1.16
Molecular pathways and therapeutic targets in lung cancer. Oncotarget (2014) 1.16
Impaired SHP2-mediated extracellular signal-regulated kinase activation contributes to gefitinib sensitivity of lung cancer cells with epidermal growth factor receptor-activating mutations. Cancer Res (2010) 1.16
Technical and implementation issues in using next-generation sequencing of cancers in clinical practice. Br J Cancer (2013) 1.16
Hierarchical modeling of activation mechanisms in the ABL and EGFR kinase domains: thermodynamic and mechanistic catalysts of kinase activation by cancer mutations. PLoS Comput Biol (2009) 1.15
Activating Mutations in ERBB2 and Their Impact on Diagnostics and Treatment. Front Oncol (2013) 1.14
Sequence and structure signatures of cancer mutation hotspots in protein kinases. PLoS One (2009) 1.14
EGFR-targeted therapy for non-small cell lung cancer: focus on EGFR oncogenic mutation. Int J Med Sci (2013) 1.14
Coot: model-building tools for molecular graphics. Acta Crystallogr D Biol Crystallogr (2004) 227.01
Crystallography & NMR system: A new software suite for macromolecular structure determination. Acta Crystallogr D Biol Crystallogr (1998) 169.28
Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr D Biol Crystallogr (1997) 137.43
Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med (2004) 71.08
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science (2004) 61.56
EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib. Proc Natl Acad Sci U S A (2004) 33.85
EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med (2005) 26.35
Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain. PLoS Med (2005) 25.93
PRODRG: a tool for high-throughput crystallography of protein-ligand complexes. Acta Crystallogr D Biol Crystallogr (2004) 23.86
Pushing the boundaries of molecular replacement with maximum likelihood. Acta Crystallogr D Biol Crystallogr (2001) 15.88
Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell (2002) 13.03
Gefitinib-sensitizing EGFR mutations in lung cancer activate anti-apoptotic pathways. Science (2004) 11.58
An allosteric mechanism for activation of the kinase domain of epidermal growth factor receptor. Cell (2006) 10.28
Novel D761Y and common secondary T790M mutations in epidermal growth factor receptor-mutant lung adenocarcinomas with acquired resistance to kinase inhibitors. Clin Cancer Res (2006) 6.91
Irreversible inhibitors of the EGF receptor may circumvent acquired resistance to gefitinib. Proc Natl Acad Sci U S A (2005) 6.82
A unique structure for epidermal growth factor receptor bound to GW572016 (Lapatinib): relationships among protein conformation, inhibitor off-rate, and receptor activity in tumor cells. Cancer Res (2004) 6.53
Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants. PLoS Med (2005) 6.04
Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity. Cancer Cell (2007) 5.95
Structure of the epidermal growth factor receptor kinase domain alone and in complex with a 4-anilinoquinazoline inhibitor. J Biol Chem (2002) 5.63
Bronchial and peripheral murine lung carcinomas induced by T790M-L858R mutant EGFR respond to HKI-272 and rapamycin combination therapy. Cancer Cell (2007) 4.85
Inhibition of drug-resistant mutants of ABL, KIT, and EGF receptor kinases. Proc Natl Acad Sci U S A (2005) 4.70
Analysis of epidermal growth factor receptor gene mutation in patients with non-small cell lung cancer and acquired resistance to gefitinib. Clin Cancer Res (2006) 4.62
Inherited susceptibility to lung cancer may be associated with the T790M drug resistance mutation in EGFR. Nat Genet (2005) 4.00
Somatic mutations of epidermal growth factor receptor signaling pathway in lung cancers. Int J Cancer (2006) 3.92
A common signaling cascade may underlie "addiction" to the Src, BCR-ABL, and EGF receptor oncogenes. Cancer Cell (2006) 3.78
Mutations and addiction to EGFR: the Achilles 'heal' of lung cancers? Trends Mol Med (2004) 3.44
Kinetic analysis of epidermal growth factor receptor somatic mutant proteins shows increased sensitivity to the epidermal growth factor receptor tyrosine kinase inhibitor, erlotinib. Cancer Res (2006) 3.34
Amino acid substitutions sufficient to convert the nontransforming p60c-src protein to a transforming protein. Mol Cell Biol (1986) 2.84
Oncogenic activity of epidermal growth factor receptor kinase mutant alleles is enhanced by the T790M drug resistance mutation. Cancer Res (2007) 2.78
Development of new mouse lung tumor models expressing EGFR T790M mutants associated with clinical resistance to kinase inhibitors. PLoS One (2007) 2.14
Allele-dependent variation in the relative cellular potency of distinct EGFR inhibitors. Cancer Biol Ther (2007) 2.12
Optimization of 6,7-disubstituted-4-(arylamino)quinoline-3-carbonitriles as orally active, irreversible inhibitors of human epidermal growth factor receptor-2 kinase activity. J Med Chem (2005) 1.99
Epidermal growth factor receptor kinase domain mutations in esophageal and pancreatic adenocarcinomas. Clin Cancer Res (2006) 1.75
Mutations of the epidermal growth factor receptor in non-small cell lung cancer -- search and destroy. Eur J Cancer (2006) 1.66
Epidermal growth factor receptor mutations in patients with non-small cell lung cancer. Cancer Res (2005) 1.47
ATP-competitive inhibitors of the mitotic kinesin KSP that function via an allosteric mechanism. Nat Chem Biol (2007) 1.39
Second-generation epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer. Oncologist (2007) 1.33
EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy. Science (2004) 61.56
Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell (2010) 39.09
The landscape of somatic copy-number alteration across human cancers. Nature (2010) 31.88
The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature (2012) 31.78
Somatic mutations affect key pathways in lung adenocarcinoma. Nature (2008) 30.02
EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med (2005) 26.35
Signatures of mutational processes in human cancer. Nature (2013) 21.63
Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma. Proc Natl Acad Sci U S A (2007) 18.83
Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis. Cancer Cell (2005) 17.41
Initial genome sequencing and analysis of multiple myeloma. Nature (2011) 17.28
The mutational landscape of head and neck squamous cell carcinoma. Science (2011) 16.88
Characterizing the cancer genome in lung adenocarcinoma. Nature (2007) 16.48
Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples. Nat Biotechnol (2013) 16.13
Effective use of PI3K and MEK inhibitors to treat mutant Kras G12D and PIK3CA H1047R murine lung cancers. Nat Med (2008) 14.47
The genomic complexity of primary human prostate cancer. Nature (2011) 14.06
High-throughput oncogene mutation profiling in human cancer. Nat Genet (2007) 12.68
A landscape of driver mutations in melanoma. Cell (2012) 12.61
High-resolution mapping of copy-number alterations with massively parallel sequencing. Nat Methods (2008) 12.56
The somatic genomic landscape of glioblastoma. Cell (2013) 11.73
Mapping the hallmarks of lung adenocarcinoma with massively parallel sequencing. Cell (2012) 11.69
Systematic RNA interference reveals that oncogenic KRAS-driven cancers require TBK1. Nature (2009) 11.46
A chromatin-mediated reversible drug-tolerant state in cancer cell subpopulations. Cell (2010) 11.20
SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N Engl J Med (2011) 11.07
Absolute quantification of somatic DNA alterations in human cancer. Nat Biotechnol (2012) 10.87
Gene expression-based survival prediction in lung adenocarcinoma: a multi-site, blinded validation study. Nat Med (2008) 10.12
Exome sequencing identifies recurrent SPOP, FOXA1 and MED12 mutations in prostate cancer. Nat Genet (2012) 9.93
EML4-ALK fusion gene and efficacy of an ALK kinase inhibitor in lung cancer. Clin Cancer Res (2008) 9.29
Evolution and impact of subclonal mutations in chronic lymphocytic leukemia. Cell (2013) 9.24
An integrated view of copy number and allelic alterations in the cancer genome using single nucleotide polymorphism arrays. Cancer Res (2004) 8.86
A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. Cell (2009) 8.64
Integrative analysis of the melanoma transcriptome. Genome Res (2010) 8.46
Dissecting therapeutic resistance to RAF inhibition in melanoma by tumor genomic profiling. J Clin Oncol (2011) 8.37
LKB1 modulates lung cancer differentiation and metastasis. Nature (2007) 7.80
Melanoma genome sequencing reveals frequent PREX2 mutations. Nature (2012) 7.77
Sequence analysis of mutations and translocations across breast cancer subtypes. Nature (2012) 7.76
Pan-cancer patterns of somatic copy number alteration. Nat Genet (2013) 7.73
TMPRSS2:ERG fusion-associated deletions provide insight into the heterogeneity of prostate cancer. Cancer Res (2006) 7.61
Integrative genomic approaches identify IKBKE as a breast cancer oncogene. Cell (2007) 7.60
SOX2 is an amplified lineage-survival oncogene in lung and esophageal squamous cell carcinomas. Nat Genet (2009) 7.48
Highly parallel identification of essential genes in cancer cells. Proc Natl Acad Sci U S A (2008) 7.45
Punctuated evolution of prostate cancer genomes. Cell (2013) 7.23
Novel mutant-selective EGFR kinase inhibitors against EGFR T790M. Nature (2009) 7.05
Sensitive mutation detection in heterogeneous cancer specimens by massively parallel picoliter reactor sequencing. Nat Med (2006) 6.96
Homozygous deletions and chromosome amplifications in human lung carcinomas revealed by single nucleotide polymorphism array analysis. Cancer Res (2005) 6.93
Phosphoglycerate dehydrogenase diverts glycolytic flux and contributes to oncogenesis. Nat Genet (2011) 6.89
Activating mutations in ALK provide a therapeutic target in neuroblastoma. Nature (2008) 6.80
High-resolution genomic profiles of human lung cancer. Proc Natl Acad Sci U S A (2005) 6.52
Lin28 promotes transformation and is associated with advanced human malignancies. Nat Genet (2009) 6.35
CDK8 is a colorectal cancer oncogene that regulates beta-catenin activity. Nature (2008) 6.24
Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy. Nat Genet (2010) 6.10
Menin associates with a trithorax family histone methyltransferase complex and with the hoxc8 locus. Mol Cell (2004) 6.08
Oncogenic transformation by inhibitor-sensitive and -resistant EGFR mutants. PLoS Med (2005) 6.04
Genomic analysis identifies association of Fusobacterium with colorectal carcinoma. Genome Res (2011) 5.97
Modeling genomic diversity and tumor dependency in malignant melanoma. Cancer Res (2008) 5.95
Structures of lung cancer-derived EGFR mutants and inhibitor complexes: mechanism of activation and insights into differential inhibitor sensitivity. Cancer Cell (2007) 5.95
Comment on "The consensus coding sequences of human breast and colorectal cancers". Science (2007) 5.88
Chromosomally unstable mouse tumours have genomic alterations similar to diverse human cancers. Nature (2007) 5.65
PF00299804, an irreversible pan-ERBB inhibitor, is effective in lung cancer models with EGFR and ERBB2 mutations that are resistant to gefitinib. Cancer Res (2007) 5.45
Mechanism and function of formins in the control of actin assembly. Annu Rev Biochem (2007) 5.36
The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies. Cancer Cell (2006) 5.34
High-throughput detection of actionable genomic alterations in clinical tumor samples by targeted, massively parallel sequencing. Cancer Discov (2011) 5.30
Integrative genome analyses identify key somatic driver mutations of small-cell lung cancer. Nat Genet (2012) 5.28
Medulloblastoma exome sequencing uncovers subtype-specific somatic mutations. Nature (2012) 5.23
Gefitinib induces apoptosis in the EGFRL858R non-small-cell lung cancer cell line H3255. Cancer Res (2004) 5.23
Predicting drug susceptibility of non-small cell lung cancers based on genetic lesions. J Clin Invest (2009) 5.07
Recurrent BRAF mutations in Langerhans cell histiocytosis. Blood (2010) 4.96
Short interfering RNAs can induce unexpected and divergent changes in the levels of untargeted proteins in mammalian cells. Proc Natl Acad Sci U S A (2004) 4.85
Bronchial and peripheral murine lung carcinomas induced by T790M-L858R mutant EGFR respond to HKI-272 and rapamycin combination therapy. Cancer Cell (2007) 4.85
Mutations in the DDR2 kinase gene identify a novel therapeutic target in squamous cell lung cancer. Cancer Discov (2011) 4.80